MinorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Vitamin D analogue (25-hydroxy metabolite)
Updated · Methodology
Mechanism
In the kidney and other tissues, the enzyme CYP27B1 converts calcifediol (25-hydroxyvitamin D3) into active calcitriol, and CYP24A1 breaks both down into inactive metabolites. Calcifediol is excreted mainly in bile, with a half-life of about 18–21 days (Hidroferol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acetylsalicylic acid is converted into salicylic acid during absorption. Salicylic acid is metabolised in the liver and, together with its metabolites, is eliminated mainly by the kidneys (Adiro SmPC, AEMPS). Liver enzyme inducers such as phenytoin, phenobarbital and primidone, and cytochrome P450 inhibitors such as ketoconazole and clarithromycin, can change calcifediol metabolism (Hidroferol SmPC, AEMPS; Rayaldee label, US Food and Drug Administration, FDA). The documents for acetylsalicylic acid do not place it in either group, and neither drug appears in the other's interaction lists (AEMPS and FDA documents for both).
Symptoms
The documents describe no symptoms linked to this combination. Excess calcifediol causes hypercalcaemia: weakness, tiredness, drowsiness, headache, loss of appetite, nausea, vomiting, constipation, thirst and passing a lot of urine. Long-term excess can lead to calcium deposits in the kidneys and blood vessels (Hidroferol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; Rayaldee label, US Food and Drug Administration, FDA). Acetylsalicylic acid increases the tendency to bleed, including from the stomach and gut, with black stools, vomiting blood or marked weakness. In people with renal impairment or poor circulation, it raises the risk of acute kidney failure (Adiro SmPC, AEMPS).
Management
According to the documents, the combination is acceptable, and the doses of acetylsalicylic acid and calcifediol need no change. No document names the pair, and acetylsalicylic acid is not among the substances that change calcifediol metabolism or absorption (Adiro and Hidroferol SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; Rayaldee label, US Food and Drug Administration, FDA). During calcifediol treatment, monitor serum 25-hydroxyvitamin D, calcium, phosphate and alkaline phosphatase, and 24-hour urinary calcium and phosphate. On maintenance treatment, repeat these tests regularly, especially 25-hydroxyvitamin D and calcium (Hidroferol SmPC, AEMPS). In chronic kidney disease, monitor calcium and phosphate regularly during calcifediol treatment. With creatinine clearance below 30 mL/min, its effect may be much weaker (Hidroferol SmPC, AEMPS). Acetylsalicylic acid is contraindicated in severe renal impairment. Use it with caution in renal impairment, heart failure and volume depletion because of the risk of acute kidney failure (Adiro SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Durlaza (aspirin) prescribing information (2015)– FDA, DailyMed setid 4c2a1403-3862-1efd-0a91-444989222b37 (New Haven Pharmaceuticals), revised 09/2015, sections 7
- AEMPS: Ficha técnica: Ácido acetilsalicílico, Adiro 100 mg (nº registro 62825) (2026)– AEMPS, CIMA, nº registro 62825 (Adiro 100 mg comprimidos gastrorresistentes EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Calcifediol, Hidroferol 0,266 mg cápsulas blandas (nº registro 80095), sección 4.5 (2025)– AEMPS, CIMA, nº registro 80095 (Hidroferol 0,266 mg cápsulas blandas, Faes Farma), revisión 06/2025, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: Rayaldee (calcifediol) prescribing information (2024)– FDA, DailyMed setid 6a95effd-32a5-46b6-a30e-7f4f9bf8cc77 (OPKO Pharmaceuticals), revised 01/2024 (version 11), sections 4, 5.1, 5.2, 7 and 12.3